| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 90999 |
|
9,181 |
796 |
$824K |
| Q4081 |
Injection, epoetin alfa, 100 units (for esrd on dialysis) |
8,346 |
737 |
$112K |
| J1756 |
Injection, iron sucrose, 1 mg |
2,263 |
824 |
$64K |
| A4657 |
Syringe, with or without needle, each |
595 |
319 |
$22K |
| J1270 |
Injection, doxercalciferol, 1 mcg |
1,746 |
204 |
$8K |
| J0887 |
Injection, epoetin beta, 1 microgram, (for esrd on dialysis) |
37 |
25 |
$845.71 |
| 83970 |
|
56 |
52 |
$676.19 |
| 82728 |
|
66 |
64 |
$224.43 |
| 83550 |
|
67 |
65 |
$144.02 |
| 83540 |
|
67 |
65 |
$106.77 |
| 85041 |
|
107 |
102 |
$50.57 |
| 85048 |
|
63 |
62 |
$41.77 |
| 82108 |
|
28 |
25 |
$6.73 |
| G0499 |
Hepatitis b screening in non-pregnant, high risk individual includes hepatitis b surface antigen (hbsag), antibodies to hbsag (anti-hbs) and antibodies to hepatitis b core antigen (anti-hbc), and is followed by a neutralizing confirmatory test, when performed, only for an initially reactive hbsag result |
79 |
64 |
$2.80 |